Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.63 |
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | HTR2B | P41595 | 3/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiflorex SCHEMBL11551709 | 0.99 | SIGMAR1 (0.62) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C | |
| SCHEMBL11547028 | 0.89 | SIGMAR1 (0.55) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C | |
| SCHEMBL11545130 | 0.87 | SIGMAR1 (0.48) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C | |
| SCHEMBL11545201 | 0.85 | SIGMAR1 (0.50) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C | |
| SCHEMBL11544879 | 0.85 | TAAR1 (0.50) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C | |
| SCHEMBL11544149 | 0.84 | SLC6A4 (0.46) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C | |
| SCHEMBL17449716 | 0.82 | HTR2A (0.44) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C | |
| SCHEMBL11547646 | 0.80 | HTR2A (0.58) | SIGMAR1SLC6A4HTR2AHTR2BHTR2C | |
| Hydrochloric Acid SCHEMBL11546088 | 0.79 | HTR2A (0.57) | SIGMAR1SLC6A4HTR2AHTR2BHTR2C | |
| Levofenfluramine SCHEMBL162006 | 0.78 | SLC6A4 (1.00) | SIGMAR1SLC6A4HTR2AHTR2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| WO-2016151295-A1 | FLUORINATION PROCESS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2016-09-29 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4148923-A | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity | SYNTHELABO (FR) | 1979-04-10 | — | — | US | claimed |
| US-4129598-A | ANOREXIGENIC AGENTS | SYNTHELABO (FR) | 1978-12-12 | — | — | US | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107229-A1 | REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| WO-1994021244-A1 | METHOD OF TREATING ADDICTIVE BEHAVIORS | HITZIG PIETR (US) | 1994-09-29 | — | — | WO | disclosed |
| US-4148923-A | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity | SYNTHELABO (FR) | 1979-04-10 | — | — | US | disclosed |
| US-4148923-A | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity | SYNTHELABO (FR) | 1979-04-10 | — | — | US | disclosed |
| US-4129598-A | ANOREXIGENIC AGENTS | SYNTHELABO (FR) | 1978-12-12 | — | — | US | disclosed |
| US-3965190-A | ANOREXIGENIC | SYNTHELABO (FR) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | SIGMAR1 773/4885SLC6A4 93/4885HTR2A 62/4885 |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | SIGMAR1 4868/4885SLC6A4 56/4885HTR2A 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.